Valeant Pharmaceuticals International, Inc. (VRX) has a high amount of executive buying compared to its large-cap peers over the past three months.
Osama Eldessouky, a Senior Officer, acquired 17,930 Common Shares on a direct ownership basis at a price of $12.510USD through an exercise of rights on June 7th, 2017. This represents a $302,631 investment into the company's shares and an account share holdings change of greater than 100%.
Valeant Pharmaceuticals is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.